Literature DB >> 17218078

Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection.

G-Y Chau1, W-Y Lui, C-W Chi, Y-P Chau, A-F Li, H-L Kao, C-W Wu.   

Abstract

BACKGROUND: Hepatocyte growth factor (HGF) is a potent hepatocyte mitogen and may stimulate the proliferation and invasiveness of human hepatocellular carcinoma (HCC) cells through the c-met receptor. This study evaluates the significance of serum HGF levels in patients undergoing HCC resection. STUDY
DESIGN: The peripheral and portal sera and HCC and non-tumorous tissues of 40 HCC patients, with tumor TNM stage I (n=12), II (n=17), and III (n=11) diseases, who underwent hepatic resection were prospectively collected. Serum HGF levels were determined by enzyme-linked immunosorbent assay. The c-met protein expressions were examined by immunohistochemistry. Median follow-up time was 69 months.
RESULTS: The prehepatectomy portal HGF levels (median, 622pg/mL) were significantly higher than peripheral HGF levels (564pg/mL) (P=0.026). The posthepatectomy portal HGF levels (699pg/mL) were significantly higher than prehepatectomy portal HGF levels (P<0.001). C-met expression was detected in 87.5% HCC and in 85.0% non-tumorous liver tissues. By Cox multivariate analysis, posthepatectomy portal HGF level >699pg/mL (P<0.001), multiple tumors (P=0.042), and TNM stages II (P=0.019) and III (P=0.009) were independent factors related with survival. Patients with a posthepatectomy portal HCG level >699pg/mL and with a positive c-met expression in HCC tissue have the worst survival.
CONCLUSIONS: In HCC patients, high peripheral and portal HGF serum levels related with poor prognosis after hepatic resection. Hepatocyte growth factor and c-met receptor can be targets of future HCC postoperative treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17218078     DOI: 10.1016/j.ejso.2006.12.007

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  15 in total

1.  The effectiveness of particle radiotherapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus.

Authors:  Shohei Komatsu; Takumi Fukumoto; Yusuke Demizu; Daisuke Miyawaki; Kazuki Terashima; Yasue Niwa; Masayuki Mima; Osamu Fujii; Ryohei Sasaki; Isamu Yamada; Yuichi Hori; Yoshio Hishikawa; Mitsuyuki Abe; Yonson Ku; Masao Murakami
Journal:  J Gastroenterol       Date:  2011-04-23       Impact factor: 7.527

Review 2.  Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging.

Authors:  Mohamed Bouattour; Audrey Payancé; Johanna Wassermann
Journal:  World J Hepatol       Date:  2015-09-18

3.  A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.

Authors:  Anthony B El-Khoueiry; Robert O'Donnell; Thomas J Semrad; Philip Mack; Suzette Blanchard; Nathan Bahary; Yixing Jiang; Yun Yen; John Wright; Helen Chen; Heinz-Josef Lenz; David R Gandara
Journal:  Cancer Chemother Pharmacol       Date:  2018-03-08       Impact factor: 3.333

Review 4.  Diagnosis of hepatocellular carcinoma.

Authors:  Asmaa I Gomaa; Shahid A Khan; Edward L S Leen; Imam Waked; Simon D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

5.  Assessment of ISGLS definition of posthepatectomy liver failure and its effect on outcome in patients with hepatocellular carcinoma.

Authors:  Kenji Fukushima; Takumi Fukumoto; Kaori Kuramitsu; Masahiro Kido; Atsushi Takebe; Motofumi Tanaka; Tomoo Itoh; Yonson Ku
Journal:  J Gastrointest Surg       Date:  2013-12-03       Impact factor: 3.452

6.  Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy.

Authors:  Kai Zhu; Zhi Dai; Jian Zhou
Journal:  Biomark Res       Date:  2013-02-05

Review 7.  Biomarker development in MET-targeted therapy.

Authors:  Yanni Zhang; Zhiqiang Du; Mingqiang Zhang
Journal:  Oncotarget       Date:  2016-06-14

Review 8.  Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front.

Authors:  Olivier De Wever; Patrick Pauwels; Bram De Craene; Michèle Sabbah; Shahin Emami; Gérard Redeuilh; Christian Gespach; Marc Bracke; Geert Berx
Journal:  Histochem Cell Biol       Date:  2008-07-22       Impact factor: 4.304

9.  Oxidation of heat shock protein 60 and protein disulfide isomerase activates ERK and migration of human hepatocellular carcinoma HepG2.

Authors:  Chung-Yi Lin; Chi-Tan Hu; Chuan-Chu Cheng; Ming-Che Lee; Siou-Mei Pan; Teng-Yi Lin; Wen-Sheng Wu
Journal:  Oncotarget       Date:  2016-03-08

10.  Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma.

Authors:  Yan-Ru Deng; Wen-Bin Liu; Zhe-Xiong Lian; Xingsheng Li; Xin Hou
Journal:  Oncotarget       Date:  2016-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.